Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 154 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy June 6, 2024 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 NF1 Associated with More Cancer Types Than Previously Known April 20, 2021 Reunión anual de la American Society of Clinical Oncology de 2022:... June 4, 2022 Load more HOT NEWS For Women With Dense Breasts, An MRI May Be A Better... A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... Snack Ideas and Tips for Better Sleep Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers
